Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Risperidone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment. Recent studies suggest that the 5-hydroxytryptamine receptor 2A (5-HT2A) gene (HTR2A) T102C and G-1438A polymorphisms may influence treatment response of risperidone or olanzapine for schizophrenia's negative symptoms (e.g., blunted affect and social withdrawal). In addition, the HTR6 T267C polymorphism has been linked to risperidone response for positive symptoms (delusions and hallucinations). The dopamine D2 receptor (DRD2) Ser311Cys polymorphism may also play a role in determining risperidone efficacy for positive, negative and cognitive symptoms, the DRD2 Ins-A2/Del-A1 diplotype may predict better risperidone response, and the DRD3 Ser311Cys variant may affect general treatment response of several atypical agents. Although investigators have started to explore genetic effects on cognitions of schizophrenia patients receiving antipsychotics, future larger sized pharmacogenetic studies on both psychotic symptoms and cognitive functions are warranted.
Lane
Hsien-Yuan
HY
China Medical University and Hospital, Department of Psychiatry, No. 2, Yuh-Der Road, Taichung, 404 Taiwan. hylane@pchome.com.tw
Lee
Cheng-Chun
CC
Liu
Yi-Ching
YC
Chang
Wen-Ho
WH
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics; D011985:Receptors, Serotonin / Q000235:genetics; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; C097216:serotonin 6 receptor; D018967:Risperidone